The Developmental Therapeutics Program focuses on finding new and innovative treatments for children with cancer. Our team develops conducts, and leads local and National Phase I and Phase II trials for children with recurrent and/or high-risk oncologic disease. Our goal is to understand and develop new treatment options for our patients that ultimately will lead to safe and effective treatments that also improve survival outcomes and quality of life.
-
We are members of the Children’s Oncology Group (COG) Phase I Consortium—one of only 21 centers in the country and one of three in the Southeast. This prestigious designation allows us to offer patients access to the most innovative treatment options.
-
We are a referral center for patients from other areas of Georgia and the U.S. who might not otherwise have access to Phase I and II clinical trials.
-
We are a member of the PBTC, which provide multiple novel therapies to children with recurrent and high-risk brain tumors.
-
Active member of NANT and TACL consortia, both of which allow our patients access to a wide range of novel therapies.
-
We are home to several innovative investigator-initiated studies that are developed by our physicians draw patients from throughout USA.
-
Our team provides state-of-the-art treatment for neuroblastoma patients through our 131I-MIBG Targeted Therapy Program. Metaiodobenzylguanidine (MIBG) is a compound that can be combined with radioactive iodine (I-131) to deliver targeted radiation therapy to neuroblastoma.
-
We partner with leading pharmaceutical companies to provide new drugs and technologies as treatment options to our patients.
-
Our team members hold numerous leadership positions in many of the national consortia mentioned above, such as the COG, PBTC, NANT and TACL. We regularly present our research results at national meetings.
-
We provide a national first-in-pediatrics Phase I trial of combining 131I-MIBG with dinutuximab, an anti-GD2 antibody, for patients with relapsed neuroblastoma followed by autologous stem cell transplant through the NANT consortium.
- 1 of only 18 131I-MIBG Therapy Sites for the Children's Oncology Group (COG) Phase III Trial
Click the link for more information about our Developmental Therapeutics Program and research.
Our developmental therapeutics team:
-
Dolly Aguilera, MD - Neuro-Oncology Expert
-
Thomas Cash, MD, MSc - Solid Tumor Expert
-
Craig Castellino, MD - Neuro-Oncology Expert
-
Jason Fangusaro, MD - Director and Neuro-Oncology Expert
-
Kelly Goldsmith, MD - Solid Tumor Expert
-
Tobey MacDonald, MD, MSc - Neuro-Oncology Expert
-
Melinda Pauly, MD - Leukemia Expert
-
Himalee Sabnis, MD, MSc - Leukemia Expert